Policymakers must turn attention to comparative efficacy data and animal testing requirement waiver, easing enforcement of clinical trial regulation, and integrating AI into clinical trials ...

Exploring the promising potential and challenges of organoids in esophagus and esophageal squamous cell carcinoma research Esophageal squamous cell ...

Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) to be completed by our partner Jazz in first-line HER2-positive ...

However, traditional clinical trial designs are often ill-suited for rare disease research with common challenges including ...

MindRank, a clinical-stage artificial intelligence (AI)-empowered drug discovery company, today announced that the first ...

MindRank doses first patient in phase III clinical trial of AI-designed oral GLP-1 receptor agonist, MDR-001: Shanghai Saturday, February 28, 2026, 18:00 Hrs [IST] MindRank, a cli ...

Explore the role of BD&L in R&D decision-making. Understand its impact on funding and market intelligence for scientists.

Shifting the focus from organ to biomarker has unlocked new options for rare and advanced cancers. Uneven efficacy, diagnostic access, and regulation still slow clinical rollout.

NSCLC remains the leading cause of cancer-related mortality worldwide, with EGFR mutations being a critical driver in approximately 10-15% of lung adenocarcinomas in Western populations, and up to 40% ...

Explore the evolution of T-cell engagers, from experimental concepts to effective therapies for haematologic malignancies.

Psychedelic drug development can still benefit from the FDA Commissioner’s National Priority Review Voucher Pilot Program, though the CNPV designation was not given to Compass Pathways’ synthetic ...

The FDA has released draft guidance on how sponsors can use Bayesian models for clinical trials.